Dr Alice Huxley, CEO & President, Speedel

Dr Alice Huxley talks to Fintan Walton about setting up Speedel and her motivations for doing so, following the merger of Ciba-Geigy and Sandoz in 1996 to create Novartis. They discuss the company's drug development programmes and how its lead compound is nearing launch. Dr Huxley also reviews the company’s business strategy and the important balance between collaborative R&D and in-house development. Finally, she outlines the reasoning behind the decision to float Speedel on the Swiss stock exchange and discusses what the future might hold for the small biotechnology company.

About Alice Huxley

Dr Alice Huxley, CEO & President of Speedel, was previously Global Project Manager at Novartis Pharma AG. She has extensive experience in research and the drug development process in a matrix-type pharmaceutical R&D organisation. Dr Huxley has led several global multidisciplinary teams that successfully brought innovative drugs to the market.